CJC-1295 (no DAC), Ipamorelin 10mg (Blend)

Key points

• The blend pairs CJC-1295 without DAC, a short acting GHRH analogue, with ipamorelin.
• Together they are meant to prompt a pulse of the body's own growth hormone.
• Neither component is licensed in the UK, and combining them does not change that.
• Both are on the WADA Prohibited List.

Quick facts

What it is

Blend of CJC-1295 (no DAC) and ipamorelin

Marketed for

Growth hormone support

UK status

Not a licensed medicine; sold for research use

In sport

Both components prohibited

How it works

CJC-1295 without DAC gives a short pulse through the GHRH receptor, while ipamorelin works through the ghrelin receptor, so the two add together. See the CJC-1295 and ipamorelin entries for detail.

What the evidence shows

There is no evidence for this blend as a specific product. The components have limited human evidence individually, and there are no controlled trials of the combination.

What it does not settle

• There are no controlled trials of this blend.
• The exact contents and ratios of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, with the added uncertainty of what a blended product contains.
• Because there is no licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

This blend has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use. Growth hormone deficiency is diagnosed and treated with licensed medicines under specialist care.

Common questions